201 related articles for article (PubMed ID: 22927933)
21. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
[TBL] [Abstract][Full Text] [Related]
22. Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice.
Chapman R; Stutz H; Jacobs W; Shephard E; Williamson AL
PLoS One; 2013; 8(8):e71601. PubMed ID: 23977084
[TBL] [Abstract][Full Text] [Related]
23. CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts.
Kato S; Shida H; Okamura T; Zhang X; Miura T; Mukai T; Inoue M; Shu T; Naruse TK; Kimura A; Yasutomi Y; Matsuo K
J Virol; 2021 Jan; 95(4):. PubMed ID: 33087465
[TBL] [Abstract][Full Text] [Related]
24. Development of a DNA-MVA/HIVA vaccine for Kenya.
Hanke T; McMichael AJ; Mwau M; Wee EG; Ceberej I; Patel S; Sutton J; Tomlinson M; Samuel RV
Vaccine; 2002 May; 20(15):1995-8. PubMed ID: 11983261
[TBL] [Abstract][Full Text] [Related]
25. Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
Im EJ; Nkolola JP; di Gleria K; McMichael AJ; Hanke T
Eur J Immunol; 2006 Oct; 36(10):2574-84. PubMed ID: 17013988
[TBL] [Abstract][Full Text] [Related]
26. Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice.
Ranganathan UD; Larsen MH; Kim J; Porcelli SA; Jacobs WR; Fennelly GJ
Vaccine; 2009 Dec; 28(1):152-61. PubMed ID: 19808028
[TBL] [Abstract][Full Text] [Related]
27. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
Kim BJ; Kim BR; Kook YH; Kim BJ
Front Immunol; 2018; 9():643. PubMed ID: 29636755
[TBL] [Abstract][Full Text] [Related]
28. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
29. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
[TBL] [Abstract][Full Text] [Related]
30. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
Hanke T; McMichael AJ; Dorrell L
J Gen Virol; 2007 Jan; 88(Pt 1):1-12. PubMed ID: 17170430
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis.
You Q; Wu Y; Wu Y; Wei W; Wang C; Jiang D; Yu X; Zhang X; Wang Y; Tang Z; Jiang C; Kong W
Int J Infect Dis; 2012 Nov; 16(11):e816-25. PubMed ID: 22921259
[TBL] [Abstract][Full Text] [Related]
32. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
[TBL] [Abstract][Full Text] [Related]
33. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
Mwau M; Cebere I; Sutton J; Chikoti P; Winstone N; Wee EG; Beattie T; Chen YH; Dorrell L; McShane H; Schmidt C; Brooks M; Patel S; Roberts J; Conlon C; Rowland-Jones SL; Bwayo JJ; McMichael AJ; Hanke T
J Gen Virol; 2004 Apr; 85(Pt 4):911-919. PubMed ID: 15039533
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors.
Joseph J; Fernández-Lloris R; Pezzat E; Saubi N; Cardona PJ; Mothe B; Gatell JM
J Biomed Biotechnol; 2010; 2010():357370. PubMed ID: 20617151
[TBL] [Abstract][Full Text] [Related]
35. Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model.
Billeskov R; Christensen JP; Aagaard C; Andersen P; Dietrich J
PLoS One; 2013; 8(8):e72185. PubMed ID: 23977248
[TBL] [Abstract][Full Text] [Related]
36. A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants.
Afolabi MO; Ndure J; Drammeh A; Darboe F; Mehedi SR; Rowland-Jones SL; Borthwick N; Black A; Ambler G; John-Stewart GC; Reilly M; Hanke T; Flanagan KL
PLoS One; 2013; 8(10):e78289. PubMed ID: 24205185
[TBL] [Abstract][Full Text] [Related]
37. The Profile of T Cell Responses in Bacille Calmette-Guérin-Primed Mice Boosted by a Novel Sendai Virus Vectored Anti-Tuberculosis Vaccine.
Hu Z; Gu L; Li CL; Shu T; Lowrie DB; Fan XY
Front Immunol; 2018; 9():1796. PubMed ID: 30123219
[TBL] [Abstract][Full Text] [Related]
38. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against
Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C
J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865
[TBL] [Abstract][Full Text] [Related]
39. Heterologous Boost Following
Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
Front Immunol; 2018; 9():2439. PubMed ID: 30425711
[TBL] [Abstract][Full Text] [Related]
40. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa.
Nkolola JP; Wee EG; Im EJ; Jewell CP; Chen N; Xu XN; McMichael AJ; Hanke T
Gene Ther; 2004 Jul; 11(13):1068-80. PubMed ID: 15164090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
